5 completed, 1 terminated. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Terminated 1 |
Follow Fluzone®: new trials by email Literature Review of Fluzone® trials Research Report on Fluzone®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Quadrivalent Influenza Vaccine Among Children Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative - Influenza | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 4363 | 2010-11-01 | 2015-07-14 |
| Study of Quadrivalent Influenza Vaccine Among Adults Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative, Investigational Trivalent Inactivated Influenza Vaccine, No Preservative, Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative - Influenza | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 739 | 2010-10-01 | 2013-10-23 |
| Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children GSK investigational vaccine GSK1557482A, Fluzone® - Influenza | Phase 3 | Completed | GlaxoSmithKline | 2116 | 2009-10-13 | 2018-09-21 |
| Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine - Influenza | Phase 3 | Terminated | Sanofi | 9172 | 2009-09-01 | 2012-08-01 |
| Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults Influenza Virus Vaccine USP Trivalent Types A and B - Orthomyxoviridae Infection, Influenza | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 4292 | 2008-10-01 | 2016-04-14 |
| Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults Fluviral™, Fluzone® - Influenza | Phase 3 | Completed | GlaxoSmithKline | 1000 | 2005-01-01 | 2017-06-08 |
Influenza, Human (6) · Orthomyxoviridae Infections (1) · Respiratory Tract Infections (1)
Sanofi Pasteur, a Sanofi Company (3) · GlaxoSmithKline (2) · Sanofi (1)
United States (5) · Puerto Rico (2)